A top Italian medical research institute claims to transform the identification of rare genetic disorders. A pilot study conducted by the Universities of Verona and Turin and published in the scientific journal Scientific Reports proved how third-generation DNA sequencing technology may detect genomic imprinting disorders with a single laboratory test. Currently, diagnosing Beckwith-Wiedemann spectrum disorder, a syndrome marked by excessive body growth and an increased risk of childhood cancer, necessitates numerous complicated tests to assess the fifth DNA base (methylated cytosine), which influences gene activity without changing its sequence. Using Oxford Nanopore Technologies' long-read technology, Italian researchers led by Massimo Delledonne and Alfredo Brusco were able to analyze the gene's chemical sequence, epigenetic modifications, and parental origin at the same time, even in cases of "mosaicism" (when the mutation occurs in only one group of cells). This critical breakthrough simplifies precision medicine, reaffirming Italy's university system as a leader in sophisticated clinical genetics research.